Literature DB >> 32290870

Response to the letter on "Comments to 'PRevention of INCisional hernia after liver transplantation (PRINC trial): study protocol for a randomized controlled trial' by Janusz Strzelczyk".

T Auer1, D Kniepeiss1,2, P Schemmer3,4.   

Abstract

Entities:  

Year:  2020        PMID: 32290870      PMCID: PMC7158066          DOI: 10.1186/s13063-020-04244-y

Source DB:  PubMed          Journal:  Trials        ISSN: 1745-6215            Impact factor:   2.279


× No keyword cloud information.
To the editor, We are very grateful to Dr. Janusz Strzelczyk for showing interest in the study protocol “PRevention of INCisional hernia after liver transplantation (PRINC trial): study protocol for a randomized controlled trial” [1] and for communicating his concerns about choosing an absorbable mesh for incisional hernia prevention after liver transplantation (LT). Indeed, to the best of our knowledge, this study is the first to investigate incisional hernia prevention with a synthetic mesh placed with the usual onlay technique during abdominal wall closure in LT. Prophylactic onlay mesh placement has been very successfully investigated in non-immunosuppressed patients, and results of the PRIMA study, a randomized controlled trial, were published recently [2]. Furthermore, synthetic meshes have been used uneventfully (especially without increased surgical side infections) in immunosuppressed patients with existing incisional hernia [3]. However, our study combines, for the first time, the prophylactic onlay approach with a resorbable mesh after LT. This study is important since (a), especially early after LT, immunosuppression is high and wound healing is compromised and (b) non-resorbable meshes are prone to get superinfected or to induce seroma with associated problems [4, 5]. Moreover, during the early post-operative course after LT, factors such as malnutrition due to end-stage liver disease and large abdominal surgery further increase the risk for inflammation, infection, and less effective collagen synthesis, resulting in a higher incidence of incisional hernia. The articles cited by Dr. Strzelczyk are not focused on the early post-transplant period. They only compare hernia following LT during the long-term follow-up with hepatopancreatic surgery [3] or focus on the late post-operative period after LT [6]. These studies have not shown an increased incidence of incisional hernia recurrence that is due to long-term immunosuppression. The clear working hypothesis is that prophylactic placement of a slow resorbable mesh during LT should protect against the most frequently occurring hernias during the early post-operative course [7]. Even with non-resorbable onlay placed meshes, recurrent hernias are reported in up to 32% of midline incisions within 5 years [8]. Most importantly, the surgical skill of abdominal wall repair is the only independent factor for the recurrence of an incisional hernia, according to the “expertise in abdominal wall surgery matters” trial, in which experts had only 12% recurrent hernias, which was almost 60% lower than in the non-expert group [9]. Results concerning the use of biological and bio-absorbable meshes were presented recently [10]. The data analysis demonstrated that both biological and bio-absorbable meshes could not be recommended for the use of complex hernia repair. In case of biological meshes increased inflammatory activity and inacceptable high recurrence rates occurred. Bio-absorbable meshes were not investigated sufficiently for a routine recommended use. The successful use of P4HB meshes was shown by a multicenter study group [11, 12] that performed a multicenter prospective study including contaminated ventral hernia repairs. The recurrence rate was 9% after 4 years in the US study group and after 2 years in the European study group. Both results were presented at international conferences (of the Americas Hernia Society and the European Hernia Society (EHS)). Our own observation study of 46 patients with complex and mostly contaminated ventral hernia showed a 4-year recurrence rate of 6% (presented at the EHS meeting, 2019). Thus, Phasix® has been chosen for the PRINC trial because of its unique properties, namely low inflammatory response, high resistance to bacterial colonization, and high mechanical strength [13, 14]. In conclusion, the PRINC study protocol is based on both local and international data and therefore represents an appropriate attempt to prevent the most prevalent early occurrence of post-transplant hernias.
  14 in total

1.  A comparative outcome analysis of incisional hernia repair in patients who underwent liver transplantation vs. those that underwent hepatopancreaticobiliary surgery using the EHS guidelines as a means of comparison.

Authors:  Hwai-Ding Lam; Aude Vanlander; Frederik Berrevoet
Journal:  Clin Transplant       Date:  2016-01-22       Impact factor: 2.863

Review 2.  The phenomenon of infection with abdominal wall reconstruction.

Authors:  Anton F Engelsman; Henny C van der Mei; Rutger J Ploeg; Henk J Busscher
Journal:  Biomaterials       Date:  2007-02-02       Impact factor: 12.479

3.  Immunosuppression is not a risk factor for 30-day wound events or additional 30-day morbidity or mortality after open ventral hernia repair: An analysis of the Americas Hernia Society Quality Collaborative.

Authors:  Ivy N Haskins; David M Krpata; Ajita S Prabhu; Luciano Tastaldi; Arielle J Perez; Chao Tu; Steven Rosenblatt; Benjamin K Poulose; Michael J Rosen
Journal:  Surgery       Date:  2018-07-18       Impact factor: 3.982

4.  Long-term follow-up (at 5 years) of midline incisional hernia repairs using a primary closure and prosthetic onlay technique: recurrence and quality of life.

Authors:  M Juvany; C Hoyuela; F Carvajal; M Trias; A Martrat; J Ardid
Journal:  Hernia       Date:  2018-01-18       Impact factor: 4.739

5.  Characterization of host response, resorption, and strength properties, and performance in the presence of bacteria for fully absorbable biomaterials for soft tissue repair.

Authors:  N F N Stoikes; J R Scott; A Badhwar; C R Deeken; G R Voeller
Journal:  Hernia       Date:  2017-08-16       Impact factor: 4.739

6.  Incisional hernia recurrence after open elective repair: expertise in abdominal wall surgery matters.

Authors:  J A Pereira; A Bravo-Salva; B Montcusí; S Pérez-Farre; L Fresno de Prado; M López-Cano
Journal:  BMC Surg       Date:  2019-08-07       Impact factor: 2.102

7.  Characterization of the Mechanical Strength, Resorption Properties, and Histologic Characteristics of a Fully Absorbable Material (Poly-4-hydroxybutyrate-PHASIX Mesh) in a Porcine Model of Hernia Repair.

Authors:  Corey R Deeken; Brent D Matthews
Journal:  ISRN Surg       Date:  2013-05-28

8.  Development of incisional herniation after midline laparotomy.

Authors:  J J Harlaar; E B Deerenberg; R S Dwarkasing; A M Kamperman; G J Kleinrensink; J Jeekel; J F Lange
Journal:  BJS Open       Date:  2017-05-10

Review 9.  What is the evidence for the use of biologic or biosynthetic meshes in abdominal wall reconstruction?

Authors:  F Köckerling; N N Alam; S A Antoniou; I R Daniels; F Famiglietti; R H Fortelny; M M Heiss; F Kallinowski; I Kyle-Leinhase; F Mayer; M Miserez; A Montgomery; S Morales-Conde; F Muysoms; S K Narang; A Petter-Puchner; W Reinpold; H Scheuerlein; M Smietanski; B Stechemesser; C Strey; G Woeste; N J Smart
Journal:  Hernia       Date:  2018-01-31       Impact factor: 4.739

10.  A post-market, prospective, multi-center, single-arm clinical investigation of Phasix™ mesh for VHWG grade 3 midline incisional hernia repair: a research protocol.

Authors:  M M J van Rooijen; A P Jairam; T Tollens; L N Jørgensen; T S de Vries Reilingh; G Piessen; F Köckerling; M Miserez; A C J Windsor; F Berrevoet; R H Fortelny; B Dousset; G Woeste; H L van Westreenen; F Gossetti; J F Lange; G W M Tetteroo; A Koch; L F Kroese; J Jeekel
Journal:  BMC Surg       Date:  2018-11-20       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.